Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Epigenetics and Nuclear Signaling >> DNA / RNA >> Translation >> Regulation
Overview
Product name
Anti-eIF2B epsilon (phospho S539) antibody
See all eIF2B epsilon products (5) ...
Description
Rabbit polyclonal to eIF2B epsilon (phospho S539)
Tested applications
Cross reactivity
Reacts with
Rat, Human
Immunogen
Synthetic peptide (Rat) derived from the region of rat eIF-2B epsilon that contains serine 535 (corresponding to serine 539 in the human sequence).
Positive control
Recombinant eIF-2B epsilon treated with GSK 3 beta and lambda phosphatase, CHO-T cells transfected with human insulin receptor (IR) +/- insulin.
Properties
Form
Liquid
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage buffer
Preservative: 0.05% Sodium Azide
Constituents: PBS, 1.0mg/ml BSA (IgG, protease free). pH 7.3
Concentration
Concentration information loading...
Purity
Immunogen affinity purified
Purification notes
Purified from rabbit serum by sequential epitope-specific chromatography. The antibody has been negatively pre-adsorbed using (i) a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated eukaryotic initiation factor 2B epsilon (eIF-2B epsilon), and (ii) a generic serine phosphorylated peptide to remove antibody that is reactive with phospho-serine, irrespective of the sequence. The final product is generated by affinity chromatography using an eIF-2B epsilon-derived peptide that is phosphorylated at serine 539.
Clonality
Polyclonal
Isotype
IgG
-
Western blot - eIF2B epsilon (phospho S539) antibody (ab4775)
(enlarge)
Applications
Show applications key
Our Abpromise guarantee covers the use of ab4775 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use a concentration of 0.1 - 1.0 µg/ml.Detects a band of approximately 88 kDa (predicted molecular weight: 82 kDa).
Target
Function
Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP.
Involvement in disease
Defects in EIF2B5 are a cause of leukodystrophy with vanishing white matter (VWM) [MIM:603896]. VWM is a leukodystrophy that occurs mainly in children. Neurological signs include progressive cerebellar ataxia, spasticity, inconstant optic atrophy and relatively preserved mental abilities. The disease is chronic-progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. While childhood onset is the most common form of the disorder, some severe forms are apparent at birth. A severe, early-onset form seen among the Cree and Chippewayan populations of Quebec and Manitoba is called Cree leukoencephalopathy. Milder forms may not become evident until adolescence or adulthood. Some females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.
Sequence similarities
Belongs to the eIF-2B gamma/epsilon subunits family.
Contains 1 W2 domain.
Target information above from: UniProt accessionQ13144
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Alternative names
- CACH antibody
- CLE antibody
- EI2BE_HUMAN antibody
see all
Database links
- Entrez Gene: 8893 Human
- Entrez Gene: 192234 Rat
- Omim: 603945 Human
- SwissProt: Q13144 Human
- SwissProt: Q64350 Rat
- Unigene: 283551 Human
- Unigene: 10607 Rat
Anti-eIF2B epsilon (phospho S539) antibody images:
Western blot - eIF2B epsilon (phospho S539) antibody (ab4775)
Predicted band size : 82 kDa
Peptide Competition: Recombinant eIF-2B episilon treated with lambda phosphatase (1) or treated with GSK-3 beta (lanes 2-5) and added to background extracts were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4oC, then were incubated with 0.50 µg/mL ab4775 antibody, following prior incubation with: no peptide (1, 2), the nonphosphopeptide corresponding to the immunogen (3), a generic phophoserine containing peptide (4), or, the phosphopeptide immunogen (5). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and signals were detected using the Tropix WesternStar method. The data show that only the peptide corresponding to ab4775 blocks the antibody signal, thereby demonstrating the specificity of the antibody. The data also show the up-regulation of the ab4775 phospho signal upon stimulation with GSK-3 beta.
References for Anti-eIF2B epsilon (phospho S539) antibody (ab4775)
This product has been referenced in:
- Yung HWet al. Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction. Am J Pathol 173:451-62 (2008). WB; Human.Read more (PubMed: 18583310) »
See 1 publication for this product
Publishing research using ab4775? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"